Literature DB >> 35292951

Treating Alcohol Use Disorder in Patients with Alcohol-Associated Liver Disease: Controversies in Pharmacological Therapy.

Claudia Tarli1, Antonio Mirijello2, Giovanni Addolorato1,3,4.   

Abstract

Alcohol use disorder (AUD) is one of the main causes of global death and disability. The liver represents the main target of alcohol damage, and alcohol-associated liver disease (ALD) represents the first cause of liver cirrhosis in Western countries. Alcohol abstinence is the main goal of treatment in AUD patients with ALD, as treatments for ALD are less effective when drinking continues. Moreover, the persistence of alcohol consumption is associated with higher mortality, increased need for liver transplantation, and graft loss. The most effective treatment for AUD is the combination of psychosocial interventions, pharmacological therapy, and medical management. However, the effectiveness of these treatments in patients with ALD is doubtful even because AUD patients with ALD are usually excluded from pharmacological trials due to concerns on liver safety. This narrative review will discuss the treatment options for AUD-ALD patients focusing on controversies in pharmacological therapy. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35292951     DOI: 10.1055/a-1798-2872

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.512


  1 in total

1.  Mortality and its association with chronic alcohol-related diseases in patients admitted to the emergency department for acute alcoholic intoxication: retrospective cohort study.

Authors:  Francesco Palmese; Maria Elena Bonavita; Giorgio Bedogni; Marco Domenicali; Enrico Pompili; Maria Teresa Migliano; Nicola Reggidori; Cecilia Di Stefano; Marta Grieco; Stefano Colazzo; Manuel Tufoni; Maurizio Baldassarre; Paolo Caraceni; Francesco Giuseppe Foschi; Fabrizio Giostra; Gabriele Farina; Rossella Del Toro
Journal:  Intern Emerg Med       Date:  2022-10-05       Impact factor: 5.472

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.